IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.496
AS - Asia 2.652
EU - Europa 1.122
SA - Sud America 440
Continente sconosciuto - Info sul continente non disponibili 167
AF - Africa 106
OC - Oceania 5
Totale 9.988
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.326
SG - Singapore 1.549
CN - Cina 520
IT - Italia 373
BR - Brasile 359
VN - Vietnam 218
FI - Finlandia 178
IE - Irlanda 111
CA - Canada 105
DE - Germania 101
HK - Hong Kong 87
GB - Regno Unito 71
NG - Nigeria 65
IN - India 64
FR - Francia 56
NL - Olanda 55
BD - Bangladesh 43
SE - Svezia 40
AR - Argentina 28
JP - Giappone 27
BE - Belgio 22
MX - Messico 22
TR - Turchia 21
IQ - Iraq 18
PL - Polonia 17
RU - Federazione Russa 17
CL - Cile 15
EC - Ecuador 15
CO - Colombia 12
CZ - Repubblica Ceca 12
ES - Italia 12
UZ - Uzbekistan 12
PK - Pakistan 11
UA - Ucraina 10
AT - Austria 9
EG - Egitto 9
IL - Israele 9
ZA - Sudafrica 9
AE - Emirati Arabi Uniti 8
CR - Costa Rica 8
ID - Indonesia 8
JM - Giamaica 8
SA - Arabia Saudita 7
HN - Honduras 6
IR - Iran 6
KE - Kenya 6
PH - Filippine 6
PT - Portogallo 6
AZ - Azerbaigian 5
EU - Europa 5
GT - Guatemala 5
KR - Corea 5
MA - Marocco 5
MY - Malesia 5
AU - Australia 4
BG - Bulgaria 4
ET - Etiopia 4
KG - Kirghizistan 4
NP - Nepal 4
PE - Perù 4
VE - Venezuela 4
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
LT - Lituania 3
MD - Moldavia 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AF - Afghanistan, Repubblica islamica di 2
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
HU - Ungheria 2
LB - Libano 2
NI - Nicaragua 2
NO - Norvegia 2
PR - Porto Rico 2
PY - Paraguay 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
AL - Albania 1
AO - Angola 1
AW - Aruba 1
BH - Bahrain 1
BM - Bermuda 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
Totale 9.820
Salva come PNG Salva come JPEG
Città #
Singapore 690
Dallas 670
Chandler 516
Wilmington 410
Ashburn 366
San Jose 305
The Dalles 199
Shanghai 182
Helsinki 177
San Mateo 162
Milan 157
Beijing 150
Ann Arbor 131
New York 127
Council Bluffs 125
Dublin 109
Boardman 97
Princeton 91
Santa Clara 89
Lawrence 82
Ho Chi Minh City 80
Leawood 77
Los Angeles 67
Hong Kong 66
Phoenix 65
Benin City 64
Rome 64
Amsterdam 48
Hanoi 45
Paris 40
Seattle 31
Woodbridge 30
Toronto 29
Buffalo 28
São Paulo 28
London 26
Fairfield 22
Montreal 22
Pune 20
Brussels 18
San Diego 18
Chicago 17
Philadelphia 17
Brooklyn 16
Orem 16
Queens 16
Warsaw 16
Atlanta 15
Figino 14
Munich 14
Naples 13
Haiphong 12
Rio de Janeiro 12
Columbus 11
Houston 11
Porto Alegre 11
Miami 10
Tashkent 10
Tokyo 10
Baghdad 9
Boston 9
Chennai 9
Da Nang 9
Kocaeli 9
Abbiategrasso 8
Assago 8
Charlotte 8
Dhaka 8
Frankfurt am Main 8
Manchester 8
Milwaukee 8
Norwalk 8
San Francisco 8
Turin 8
Andover 7
Brasília 7
Denver 7
Kingston 7
Las Vegas 7
Raleigh 7
Salvador 7
Washington 7
Belo Horizonte 6
Bogotá 6
Brno 6
Cairo 6
Falkenstein 6
Guayaquil 6
Istanbul 6
Jeddah 6
Jersey City 6
Monmouth Junction 6
North Bergen 6
Redwood City 6
San José 6
Biên Hòa 5
Chengdu 5
Curitiba 5
Falls Church 5
Florence 5
Totale 6.248
Salva come PNG Salva come JPEG
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 170
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 159
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 146
Tivantinib for hepatocellular carcinoma 141
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 137
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 128
Biomarkers in Hepatocellular Carcinoma-Letter 127
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 122
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 121
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 121
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 121
COVID-19 and liver cancer clinical trials: not everything is lost 120
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 120
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 119
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 118
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 115
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 113
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 112
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 111
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 111
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 109
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 106
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 106
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 105
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 104
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 103
Cabozantinib for the treatment of hepatocellular carcinoma 102
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 101
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 101
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 100
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 99
Reply to Y. Pointreau et al 99
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 98
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 98
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 97
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 97
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 96
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 95
Shaping the landscape of immune oncology in hepatocellular carcinoma 94
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 94
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 94
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 93
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 93
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 92
Role of liver biopsy in hepatocellular carcinoma 91
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 91
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 91
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 90
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 90
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 90
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 90
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 89
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 88
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 88
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 87
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 86
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 85
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 85
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 84
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 84
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 83
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 83
Regorafenib for the treatment of unresectable hepatocellular carcinoma 82
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 82
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 81
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 81
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 80
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 80
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 80
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 79
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 79
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 79
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 79
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 78
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 78
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 78
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 77
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 76
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 75
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 73
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 73
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 73
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 73
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 72
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 72
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 72
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 72
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 72
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 70
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 68
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 68
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 67
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 67
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 67
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 66
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 66
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 65
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 65
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 64
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 63
Totale 9.275
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.760
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.760
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022528 0 0 0 105 16 14 24 80 64 104 82 39
2022/20231.466 194 81 136 188 147 118 13 113 230 104 114 28
2023/2024939 72 77 170 50 35 145 82 34 9 15 104 146
2024/20251.205 46 22 3 29 33 128 120 108 200 244 117 155
2025/20263.634 492 668 176 314 80 157 869 130 175 199 171 203
2026/20271.422 428 308 508 178 0 0 0 0 0 0 0 0
Totale 9.988